Release of Part 1 of EXPOSED scheduled for the week of May 20. EXPOSED is a four-part series of short films that tell the story of the deadly global epidemic of tuberculosis. The series will portray the struggles of four inspiring individuals - an ...
Watch Video
A video from Medecins Sans Frontieres entitled "Multidrug-Resistance Tuberculosis: No Promises" on the situation of children affected with MDR-TB. It highlights the dire plight of children being treated for MDR-TB in Tajikistan....
Watch Video
This week we highlight an interview with Dr. Andrew Vernon, the Chief, Clinical Research Branch, Division of Tuberculosis Elimination at the U.S. Centers for Disease Control and Prevention (CDC). He discusses the progress made in TB drug developmen...
Watch Video
This week we highlight an interview with Dr. Douglas Lowrie, a Senior Research Fellow at Fudan University's Shanghai Public Health Clinical Center in China. He discusses the extent of the problem of TB in China and innovative research on enhancing ...
Watch VideoGo to Meetings tab in menu or click here.
Presentations, photos, and other materials can be found by going to “Meetings” on the menu bar or clicking here.
Release of Part 1 of EXPOSED scheduled for the week of May 20. EXPOSED is a four-part series of short films that tell the story of the deadly global epidemic of tuberculosis. The series will portray the struggles of four inspiring individuals – an MDR-TB survivor, a TB doctor, a clinical trial volunteer, and a TB vaccine researcher – bringing viewers to the forefront of the race against tuberculosis.
Treatment Action Group (TAG) recently released its Spring 2013 issue of tagline, which contains three articles about TB research that might be of interest to you– 1) on rifapentine research and access, 2) on adaptive clinical trial designs, and 3) on pediatric drug development needs.
An online tool that invites developers to submit their discovery programs so we can provide a more complete snapshot of current global efforts.
View Pipeline
An online tool that invites developers to submit their TB drug candidates so we can provide a more complete snapshot of current global efforts.
View Pipeline
A growing collection of resources to help access Tools, Knowledge, Facilities, and People in the TB drug development R&D community.
View TB ResourcesToday's TB drug regimen takes too long to be effective and requires too many medications. Treatment of drug-sensitive disease requires 6-9 months whereas treatment of drug-resistant TB is even lengthier, taking 18-24 months or longer.
Read More
To accelerate the discovery and development of new drugs for the treatment of tuberculosis by bringing together the stakeholders in TB Drug Development, including the patients themselves.
Read More »
The WGND is composed of diverse interested stakeholders in TB drug development, including those working in TB drug R&D, regulators, public health workers, funders, community representatives, advocates and policy-makers.
Read More »